{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/220977408"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "Maximum Tolerated Dose (MTD) [ Time Frame: Each patient will be followed for 22 days ] [ Designated as safety issue: Yes ]Patients will be sequentially assigned to increasing doses of Dexanabinol, to establish the MTD (highest dose it is safe to give patients) or alternatively the Maximum Administered Dose(MAD)." ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "clinicaltrials.gov" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/78036867"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/220977408"] } } }
